ClinicalTrials.gg
CompletedNCT00933868Updated May 25, 2012

Magnesium Chloride Versus Placebo in Patients Who Have Had a Stroke

A Phase 2/3 interventional study of Magnesium Chloride and Placebo in Stroke, sponsored by Relox Medical, LLC. Completed at 3 sites in United States. Open to participants aged 18 Years to 90 Years. Per ClinicalTrials.gov, last updated 2012-05-25.

Sponsored by Relox Medical, LLC · Phase 2/3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
81
Allocation
Randomized
Ages
18 Years to 90 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 1,995 studies in Stroke with a site in United States — 395 open to participants now, 492 under way, 17 of them phase 3. Stroke · United States.

Enrollment
481st of 1,621
81 · median 40
Started
2009
with 50 others
Phase 2/3
26 of 1,995
5 open now
Registered
355th of 1,995
by date

Among the 1,995 studies in Stroke with a site in United States, this one is the 481st largest by enrollment of the 1,621 interventional ones that give a count, is one of 51 that started in 2009, is one of 26 in phase 2/3, and was the 355th registered.

Stroke

8,269 studies on the registry are indexed under Stroke; 2,062 are open to participants now.

Browse Stroke studies →

Open to participants now

395 of the 1,995 studies in Stroke with a site in United States are open now. Recruiting first, the newest first:

390 more — sign in →

All 395 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 1,418 Stroke studies recruiting now, 696 (49%) set no upper age limit and 282 (20%) stop at 75 or younger; 77 take children under 18; 196 take healthy volunteers.

This study: 18 Years to 90 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,995 studies in Stroke with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the effect of six intravenous (IV) infusions of magnesium chloride versus placebo in patients who have residual muscle weakness from a stroke that occurred three months to four years ago.

Read the detailed description

The hypothesis being tested is that these six treatments will improve muscle weakness and lead to an improvement in functioning/activities of daily living as measured by the 100-point Barthel index, three months after their last treatment versus their baseline measure, and that the mean difference between the treatment and placebo groups of patients will be at least three points in this index.

03

Conditions studied

  • Stroke

Browse trials for

Keywords

  • A stroke that occurred three months to four years ago
04

Who can participate

Ages eligible
18 Years to 90 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Subjects of either sex above 18 years of age
  2. Documented history of stroke 3 months to four years ago
  3. Subjects may have had two or more strokes
  4. Must have residual muscle weakness with a 25% or greater difference in strength between the right and left sides of the body
  5. Must be assessed as a 2 or 3 on the Modified Rankin Scale
  6. Must have a Barthel score at or below 85

Exclusion criteria

Exclusion Criteria:

  1. Any traumatic brain injury or other brain injury apart from stroke
  2. Renal insufficiency or renal failure
  3. Any medical or physical condition that would interfere with the measurements to be conducted
  4. Any physical therapy in a facility outside their home within three days of screening
05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
81 participants (actual)

Study arms

  • Experimental
    Magnesium infusion in patients breathing 100% oxygen

    Patients will be given six infusions over three weeks. Each infusion will last between 4 and 10 minutes. They will then return to clinic in 1,2 and 3 months for the same tests (but no infusions will be given).

    Drug: Magnesium Chloride

  • Placebo comparator
    Placebo infusion

    The patients will receive six placebo infusions after which they will return to clinic at one, two and three months. At the conclusion of the trial those patients who received placebo may elect to receive the active treatment in another (open label) trial that will begin shortly after this one concludes.

    Drug: Placebo

Interventions

  • An infusion of magnesium chloride will be given over 4 to 10 minutes in patients breathing 100% oxygen

  • DrugPlacebo

    A saline placebo will be given as an infusion (six infusions over a three week period) in a double blind manner with the active test agent

06

What researchers measure

Primary outcomes

  1. Barthel Index

    Time frame: Infusions are given over 3 weeks and subjects are followed-up at 1, 2 and 3 month intervals after the infusions

Secondary outcomes

  1. Improvement in muscle strength and function

    Time frame: Infusions are given over 3 weeks and subjects are followed-up at 1, 2 and 3 month intervals after the infusions

  2. Change in the Mini-mental status examination

    Time frame: Infusions are given over 3 weeks and subjects are followed up at 1,2, and 3 months after the infusions

  3. Change in balance, coordination, range of motion

    Time frame: Infusions are given over 3 weeks and subjects are followed-up at 1, 2 and 3 months after the infusions

  4. Incidence of adverse events and changes in vital signs

    Time frame: Infusions are given over 3 weeks and subjects are followed-up at 1, 2, and 3 months after the infusions

07

Study locations

3 sites
  • Born Preventive Healthcare Clinic, PC
    Grand Rapids, Michigan 49512, United States
  • Schachter Center for Complementary Medicine
    Suffern, New York 10901, United States
  • Comprehensive Heart Care Inc.
    Toledo, Ohio 43606, United States
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Apr 2009, a primary completion of May 2010 and a completion of Jul 2010. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 30, 2009
First posted
Jul 7, 2009
Start
Apr 2009
Primary completionActual
May 2010
CompletionActual
Jul 2010
Last update
May 25, 2012
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 25, 2012, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00933868
Lead sponsor
Relox Medical, LLC
Responsible party
Bert Spilker (Lead Principal Investigator, Relox Medical, LLC) — Principal investigator
First posted
Jul 7, 2009
Start date
Apr 2009
Primary completion
May 2010
Completion
Jul 2010
Last update
May 25, 2012

Study contacts

Bert Spilker, PhD, MD
principal investigator · President, Bert Spilker & Associates, LLC

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2010. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Magnesium Chloride

Start the discussion